ECO 2026 12 - 15 May 2026

Once-Weekly Subcutaneous CagriSema Does Not Affect the Exposure of Atorvastatin or Warfarin in People Living With Overweight or Obesity 

Authors :

Valdemar Funch Uhre1; Niels-Peter Becker1; Katrine Kirkeby1; Michal Tomasz Marzec1; Gaetano Morelli2; Louise Witten1

Affiliations
View Details Hide Details
{{ getPageNum(PDFPage) }}
Download .PDF
Keywords
Obesity
Congress poster
GLP-1 RA
Cagrilintide
Pre-clinical